tiprankstipranks
Advertisement
Advertisement
Charles River announces ‘continued momentum’ in digital pathology platform
PremiumThe FlyCharles River announces ‘continued momentum’ in digital pathology platform
28d ago
Charles River Labs: Buy Rating Reiterated as 2026 Outlook Strengthens; $235 Price Target Maintained
Premium
Ratings
Charles River Labs: Buy Rating Reiterated as 2026 Outlook Strengthens; $235 Price Target Maintained
29d ago
Cyber Threats Loom Over Charles River Laboratories: Rising AI-Enabled Attacks, Third-Party Risks, and Potential Financial Fallout
Premium
Company Announcements
Cyber Threats Loom Over Charles River Laboratories: Rising AI-Enabled Attacks, Third-Party Risks, and Potential Financial Fallout
1M ago
Charles River Labs Balances Q1 Setback With 2H Rebound
PremiumCompany AnnouncementsCharles River Labs Balances Q1 Setback With 2H Rebound
1M ago
Charles River reports Q1 adjusted EPS $2.06, consensus $1.94
Premium
The Fly
Charles River reports Q1 adjusted EPS $2.06, consensus $1.94
1M ago
Charles River backs FY26 adjusted EPS view $10.80-$11.30, consensus $11.07
Premium
The Fly
Charles River backs FY26 adjusted EPS view $10.80-$11.30, consensus $11.07
1M ago
Charles River price target raised to $210 from $200 at Barclays
PremiumThe FlyCharles River price target raised to $210 from $200 at Barclays
2M ago
Charles River initiated with an Outperform at RBC Capital
Premium
The Fly
Charles River initiated with an Outperform at RBC Capital
2M ago
Charles River price target lowered to $160 from $165 at JPMorgan
Premium
The Fly
Charles River price target lowered to $160 from $165 at JPMorgan
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100